GALMED PHARMACEUTICALS LTD (GLMD) Stock News

USA - Nasdaq - NASDAQ:GLMD - IL0011313900 - Common Stock

0.9399 USD

+0.02 (+1.74%)

Last: 11/28/2025, 3:48:21 PM

0.9101 USD

-0.03 (-3.17%)

After Hours: 11/28/2025, 3:48:21 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GLMD Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Chartmill - Mentions: SRDX KXIN APLT ANVS ...

News Image

On Tuesday, there are stocks with unusual volume. Let's take a look.

2 days ago - By: Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

10 days ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

11 days ago - By: Stocktwits

Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough — Retail Sees Dilution Risks

11 days ago - By: Benzinga - Mentions: AIM NUVL VTGN VYNE ...

12 Health Care Stocks Moving In Monday's After-Market Session

11 days ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

2 months ago - By: Benzinga - Mentions: PTIX CASI TLPH NDRA ...

12 Health Care Stocks Moving In Monday's After-Market Session

3 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

7 months ago - By: Stocktwits

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’

7 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

7 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

8 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

8 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

8 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

8 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

8 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

a year ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA NVS MRK ...

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

a year ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases